Delirium Market Size

ID: MRFR/Pharma/4394-CR

128 Pages

Rahul Gotadki

January 2024

Delirium Market Research Report Information by Type (Hyperactive, Hypoactive, Mixed), By Diagnosis and treatment (Diagnosis, Treatment) By End-User (Hospitals, Specialty Care, Research Centers), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Delirium Size

Delirium Market Growth Projections and Opportunities

The pervasiveness and incidence of delirium shift internationally, impacted by elements like age, fundamental ailments, utilization of medications, and hospitalization, driving business sector interest for symptomatic devices and treatment choices taking special care of impacted people. The maturing population, especially in established nations, adds to the rising predominance of delirium, as more established people are more defenseless to delirium because age related mental degradation and higher pervasiveness of comorbidities, driving business sector growth through more appeal for geriatric care administrations. Fundamental ailments like dementia, contamination, electrolyte imbalance nature, and neurological problems increment the gamble of delirium, impacting market interest for interventions focusing on the hidden causes and comorbidities related with delirium. The utilization of specific medications, like tranquilizers, anticholinergics, and narcotics, builds the risk of delirium, driving business sector interest for elective medications with a lower chance of delirium enlistment and pharmacological interventions focusing on delirium side effects. Hospitalization, especially in intensive care units (ICUs) and postoperative settings, builds the risk of delirium because of variables like lack of sleep, immovable condition, tangible hardship, and prescription organization, driving business sector growth through more appeal for delirium counteraction and the executives procedures in healthcare settings. Varieties in healthcare foundation across districts influence admittance to specific geriatric care administrations, mental offices, and intensive care units fit for overseeing delirium, affecting business sector interest for therapy choices and healthcare administrations. Varieties in health care coverage inclusion for delirium treatment influence market openness and reasonableness for patients, impacting treatment choices and healthcare supplier proposals in regards to delirium the board. Advancing administrative systems for drugs, clinical gadgets, and mental care influence market passage methodologies for organizations creating items and administrations connected with delirium treatment, affecting item accessibility, estimating, and contest elements. Financial factors, for example, healthcare use, Gross domestic product per capita, and healthcare foundation improvement impact market elements by deciding the moderateness and directness of treatment choices for patients with delirium in various areas.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market valuation of the Delirium Market by 2035?

The Delirium Market is projected to reach a valuation of 0.5967 USD Billion by 2035.

What was the market valuation of the Delirium Market in 2024?

In 2024, the Delirium Market had a valuation of 0.338 USD Billion.

What is the expected CAGR for the Delirium Market during the forecast period 2025 - 2035?

The expected CAGR for the Delirium Market during the forecast period 2025 - 2035 is 5.3%.

Which companies are considered key players in the Delirium Market?

Key players in the Delirium Market include Johnson & Johnson, Pfizer Inc., and Bristol-Myers Squibb, among others.

What are the main segments of the Delirium Market?

The main segments of the Delirium Market include Type, Diagnosis and Treatment, and End User.

How did the Hyperactive segment perform in 2024?

In 2024, the Hyperactive segment was valued at 0.1014 USD Billion.

What is the projected value of the Treatment segment by 2035?

The Treatment segment is projected to reach a value of 0.358 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Delirium Market Size was estimated at 0.338 USD Billion in 2024. The Delirium industry is projected to grow from 0.3559 in 2025 to 0.5967 by 2035, exhibiting a compound annual growth rate (CAGR) of 5.3 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Delirium Market is experiencing a dynamic shift driven by increased awareness and technological advancements.

North America remains the largest market for delirium management, reflecting a robust healthcare infrastructure.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and awareness.
The hyperactive segment continues to dominate the market, while the hypoactive segment is witnessing rapid growth due to evolving diagnostic criteria.
Key market drivers include the rising incidence of delirium and advancements in diagnostic technologies, which are shaping care delivery.

Market Size & Forecast

2024 Market Size	0.338 (USD Billion)
2035 Market Size	0.5967 (USD Billion)
CAGR (2025 - 2035)	5.3%
Largest Regional Market Share in 2024	North America

Major Players

Johnson & Johnson (US), Pfizer Inc. (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Roche Holding AG (CH), Novartis AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Sanofi S.A. (FR)

Market Trends

The Delirium Market is currently experiencing a notable evolution, driven by a growing awareness of the condition and its implications for patient care. Healthcare professionals are increasingly recognizing the importance of early diagnosis and intervention, which appears to enhance patient outcomes. This shift in focus is likely influenced by a broader understanding of the cognitive impairments associated with delirium, prompting the development of targeted treatment protocols. Furthermore, advancements in technology and research methodologies are facilitating a more nuanced understanding of the underlying mechanisms of delirium, potentially leading to innovative therapeutic options. In addition, the Delirium Market is witnessing a rise in collaborative efforts among healthcare providers, researchers, and pharmaceutical companies. These partnerships seem to foster a more integrated approach to managing delirium, emphasizing the need for comprehensive care strategies. As the healthcare landscape continues to evolve, the emphasis on patient-centered care is likely to shape the future of the Delirium Market, encouraging the adoption of holistic treatment approaches that address both the psychological and physiological aspects of the condition.

Increased Awareness and Education

There is a growing emphasis on educating healthcare professionals about delirium, which may lead to improved recognition and management of the condition. This trend suggests that enhanced training programs could significantly impact patient outcomes.

Technological Advancements in Diagnosis

Innovations in diagnostic tools and technologies are emerging, potentially allowing for quicker and more accurate identification of delirium. This trend indicates a shift towards more efficient healthcare practices, which may improve treatment timelines.

Collaborative Care Models

The Delirium Market is seeing a rise in collaborative care models that involve multidisciplinary teams. This approach appears to enhance the quality of care provided to patients, as it integrates various expertise to address the complexities of delirium.

Delirium Market Market Drivers

Rising Incidence of Delirium

The increasing incidence of delirium, particularly among the elderly population, is a notable driver in the Delirium Market. Studies indicate that approximately 15 to 30% of hospitalized older adults experience delirium, which can lead to longer hospital stays and increased healthcare costs. This rising prevalence necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. Furthermore, the aging population is projected to reach 1.5 billion by 2050, suggesting a sustained demand for delirium management solutions. As healthcare systems adapt to this demographic shift, the Delirium Market is likely to expand, with a focus on innovative treatment modalities and preventive strategies.

Increased Focus on Mental Health

The growing emphasis on mental health awareness is influencing the Delirium Market. As healthcare providers recognize the psychological aspects of delirium, there is a shift towards integrated care models that address both physical and mental health needs. This holistic approach is likely to enhance treatment efficacy and patient satisfaction. Moreover, mental health initiatives are gaining traction, with funding for research and treatment programs on the rise. This trend is expected to foster the development of new therapeutic options specifically targeting delirium, thereby expanding the Delirium Market. The intersection of mental health and delirium management is becoming increasingly relevant in contemporary healthcare.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are transforming the Delirium Market. Enhanced imaging techniques and biomarkers are facilitating earlier and more accurate detection of delirium. For instance, the integration of artificial intelligence in diagnostic processes is showing promise in identifying at-risk patients. The market for diagnostic devices is expected to grow significantly, with estimates suggesting a compound annual growth rate of over 10% in the coming years. This growth is driven by the need for timely interventions, which can mitigate the adverse effects of delirium. Consequently, the Delirium Market is witnessing an influx of innovative diagnostic solutions that improve patient outcomes.

Regulatory Support for Innovative Therapies

Regulatory bodies are increasingly supporting the development of innovative therapies for delirium, which is a crucial driver in the Delirium Market. Initiatives aimed at expediting the approval process for new drugs and treatment protocols are emerging, reflecting a commitment to addressing this complex condition. For instance, the introduction of fast-track designations for promising therapies can significantly shorten the time to market. This regulatory environment encourages pharmaceutical companies to invest in research and development, potentially leading to breakthroughs in delirium treatment. As a result, the Delirium Market is poised for growth, with a variety of new therapeutic options likely to enter the market in the near future.

Growing Demand for Comprehensive Care Solutions

The demand for comprehensive care solutions in the Delirium Market is on the rise, driven by the need for integrated treatment approaches. Healthcare providers are increasingly recognizing that delirium management requires a multifaceted strategy, encompassing medical, psychological, and social support. This shift is prompting the development of collaborative care models that involve multidisciplinary teams. The market for such comprehensive solutions is expected to expand, as they are associated with improved patient outcomes and reduced healthcare costs. Furthermore, the emphasis on value-based care is likely to propel investments in comprehensive delirium management programs, thereby enhancing the Delirium Market.

Market Segment Insights

Delirium Market Type Insights

The Delirium Market segmentation, based on type, includes Hyperactive, Hypoactive, Mixed. The Hypoactive segment is to hold the majority share in 2022 in the Delirium Market revenue. Due to hypoactive characterized by subdued motor activity, poses a unique challenge, necessitating specialized interventions. Pharmaceutical advancements and targeted therapeutic approaches are driving innovation in this market, providing novel treatment options. Healthcare providers are increasingly recognizing the importance of early detection and tailored interventions for hypoactive delirium, contributing to market expansion.

January 7, 2019: Dr. Lata McGinn, Cognitive Behavioural Consultants and Professor at Yeshiva University, announced the launch of the New International Cognitive Behaviour Therapy Organization. The organization is dedicated to the promotion of health and well-being through the scientific development and implementation of evidence-based cognitive behavioural strategies designed to evaluate, prevent, and treat mental conditions and illnesses.

Delirium Market Indication Insights

The Delirium Market segmentation is based on a Diagnosis and treatment, that includes Diagnosis, and Treatment. The diagnosis segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to integration of artificial intelligence and machine learning algorithms revolutionizing diagnostic approaches, offering more efficient and objective assessments. The growing emphasis on early detection and intervention is driving investments in research and development, fostering a dynamic landscape for diagnostic innovations in the Delirium Market, ultimately improving patient care and outcomes.

Figure 2: DELIRIUM MARKET, BY INDICATION, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Delirium Market End User Insights

The Delirium Market segmentation is based on end-user that includes Hospitals, Speciality Care, and Research Centers. The hospitals segment has dominated the market in 2022 and homecare is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to hospitals increasingly recognizing the significance of delirium in patient care, there is a growing demand for effective solutions and interventions. Delirium Market management has become a focal point in hospitals, driven by factors such as an aging population and the recognition of delirium's impact on healthcare outcomes.

Hospitals are investing in staff training, awareness programs, and specialized resources to address delirium promptly. The integration of comprehensive delirium protocols within hospital workflows is contributing to improved patient care, creating a positive trajectory for the growth of delirium-related services and products in the global healthcare landscape.

Get more detailed insights about Delirium Market Research Report — Global Forecast till 2035

Regional Insights

North America : Leading Market for Delirium Market

North America is the largest market for delirium treatments, accounting for approximately 45% of the global market share. The region's growth is driven by an aging population, increasing awareness of delirium, and advancements in treatment options. Regulatory support from agencies like the FDA has also catalyzed market expansion, facilitating quicker approvals for innovative therapies. The demand for effective management of delirium in hospitals and long-term care facilities is on the rise, further propelling market growth. The United States is the primary contributor to this market, with significant investments from key players such as Johnson & Johnson, Pfizer, and Merck. Canada follows as the second-largest market, holding around 10% of the share. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to develop effective solutions for delirium management. The presence of robust healthcare infrastructure enhances the market's potential.

Europe : Emerging Market with Potential

Europe is witnessing significant growth in the delirium market, holding approximately 30% of the global share. The region's expansion is fueled by increasing incidences of delirium, particularly among the elderly, and a growing focus on mental health awareness. Regulatory frameworks, such as the European Medicines Agency's guidelines, are encouraging the development of new therapies, thus enhancing market dynamics. Countries like Germany and the UK are leading this growth, driven by their advanced healthcare systems and research initiatives. Germany stands out as the largest market in Europe, followed closely by the UK and France. The competitive landscape is marked by the presence of major players like Roche and Novartis, who are actively involved in research and development. The collaboration between pharmaceutical companies and healthcare providers is fostering innovation in treatment options, making Europe a promising region for future investments in the delirium market. The emphasis on patient-centered care is also shaping market strategies.

Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is emerging as a rapidly growing market for delirium treatments, currently holding about 15% of the global market share. The growth is driven by increasing healthcare expenditure, rising awareness of mental health issues, and a growing elderly population. Countries like Japan and China are at the forefront, with government initiatives aimed at improving healthcare services and mental health support. Regulatory bodies are also becoming more proactive in approving new treatments, which is expected to further boost market growth. Japan is the largest market in the region, followed by China and Australia. The competitive landscape is evolving, with both local and international players vying for market share. Key companies such as Eli Lilly and AstraZeneca are investing in research and development to introduce innovative solutions for delirium management. The increasing collaboration between healthcare providers and pharmaceutical companies is expected to enhance treatment accessibility and effectiveness in the region.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region represents an untapped market for delirium treatments, currently holding about 10% of the global market share. The growth is primarily driven by increasing healthcare investments and a rising awareness of mental health issues. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at improving healthcare infrastructure and mental health services. Regulatory bodies are beginning to recognize the importance of mental health, which is expected to catalyze market growth in the coming years. South Africa is the largest market in this region, followed by the UAE. The competitive landscape is characterized by a mix of local and international players, with companies like Sanofi and Merck making significant inroads. The focus on improving healthcare access and quality is shaping market strategies, and the increasing collaboration between stakeholders is expected to drive innovation in delirium management solutions.

Key Players and Competitive Insights

The Delirium Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such as Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland) dominate the Delirium Market due to Type differentiation, financial stability, strategic services, and diversified regional presence.

The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global Delirium industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs.

Key Companies in the Delirium Market market include

Industry Developments

April 2023, Otsuka Pharmaceutical Co., Ltd (Japan) got approval from US Food and Drug Administration for drug ABILIFY ASIMTUFII (aripiprazole) approval for the treatment of schizophrenia or delirium as well as maintenance monotherapy in people with bipolar I disorder. Moreover, this drug effectively treats delirium.

In April 2023, The US Food and Drug Administration approved Teva Pharmaceutical Industries’ UZEDY (risperidone) an injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia and delirium in adults. Additionally, those who are physically ill could use this medication to decrease the behavioral and cognitive symptoms of delirium.

In September 2022, Ceribell, Inc (US) received US FDA breakthrough device designation from its device Ceribell system for the treatment of delirium indication. This device operates machine learning to examine electroencephalography (EEG) signals to detect delirium.

Future Outlook

Delirium Market Future Outlook

The Delirium Market is projected to grow at a 5.3% CAGR from 2024 to 2035, driven by increasing awareness, advancements in treatment options, and an aging population.

New opportunities lie in:

Development of telehealth platforms for remote patient monitoring
Investment in AI-driven diagnostic tools for early detection
Expansion of specialized training programs for healthcare professionals

By 2035, the Delirium Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

Market Segmentation

Delirium Market Type Outlook

Hyperactive
Hypoactive
Mixed

Delirium Market End User Outlook

Hospitals
Speciality Care
Research Centers

Delirium Market Diagnosis and Treatment Outlook

Diagnosis
Treatment

Report Scope

MARKET SIZE 2024	0.338(USD Billion)
MARKET SIZE 2025	0.3559(USD Billion)
MARKET SIZE 2035	0.5967(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.3% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in digital health technologies enhance early detection and management in the Delirium Market.
Key Market Dynamics	Rising awareness of delirium management drives innovation in treatment options and enhances patient care strategies.
Countries Covered	North America, Europe, APAC, South America, MEA